AtaiBeckley

AtaiBeckley N.V. is a clinical-stage biopharmaceutical company focused on the research, development and clinical advancement of therapeutic candidates designed to address mental health conditions. The company was formed through the strategic combination of atai Life Sciences and Beckley Psytech, bringing together complementary pipelines and expertise in psychedelic-based and neuroplastogen therapeutic approaches.

The company's pipeline includes investigational compounds targeting treatment-resistant depression, social anxiety and related psychiatric disorders. AtaiBeckley's clinical programs span multiple modalities and formulations, supported by ongoing Phase 2 and preparatory Phase 3 studies. The company's research encompasses psychedelic-derived therapeutics alongside other novel mechanisms of action, reflecting a diversified approach to developing treatments for conditions that remain inadequately addressed by existing pharmacological options.

AtaiBeckley operates a platform model that encompasses translational research, clinical trial execution and regulatory engagement across multiple jurisdictions. The company's strategy centers on advancing a portfolio of differentiated candidates through clinical development, with the goal of bringing new treatment options to patients with mental health disorders. AtaiBeckley operates within the psychedelic therapeutics segment of the broader biopharmaceutical industry.